



Facts & Figures



Global Footprint

17 state-of-the-art production facilities (incl. 4 Joint Ventures) **15** countries, including all major pharma hubs



€986

million revenue*
(+5.8% at constant currencies)

€280

million EBITDA
Margin: 28.4 %



>1,300

patents, patent applications,
utility models, and designs
filed by R&D team

125

employees in R&D,
collaborating with a
network of partners

On average, more than 30,000 injections per minute are provided to patients worldwide through a SCHOTT Pharma product.

>13

billion products
delivered every year



Glass syringes



Polymer syringes



Cartridges



Vials



Ampoules



Broad
ready-to-use
portfolio

*All figures in this document refer to the financial year 2025.



SCHOTT Pharma at a glance

Market & Customers

The **top 30** global
pharma companies use
SCHOTT Pharma's solutions.

>1,800
customers worldwide



Big pharma
innovators



Leading
CDMOs



Biotech &
start-ups

Growth opportunities from structural trends

GLP-1 drugs

Increasing demand to treat
type-2 diabetes, obesity



SCHOTT Pharma has long-
term contracts with the leading
GLP-1 players

Antibody-drug conjugates (ADCs)

Innovative ADC therapies need to be
lyophilized to ensure drug efficacy



SCHOTT Pharma offers specialty
vials that fully eliminate fogging
thanks to a hydrophobic
inner coating

Homecare solutions

allow subcutaneous self-injection of small
and large drug doses at
home, thus reducing healthcare cost



SCHOTT Pharma contributes to
fully integrated systems from
device manufacturers with primary
packaging, e.g. prefillable syringes
and cartridges in small and large
formats

Manufacturing transformation

Smaller patient populations
require more flexible filling lines



SCHOTT Pharma offers pre-
sterilized, ready-to-use products
for utmost flexibility



SCHOTT Pharma at a glance

ESG Responsibility



↓

>60%
reduced CO₂
emissions since 2019¹

100 %
already using renewable
electricity worldwide

→ Closed-loop
recycling pilot
projects started
e.g. polymer trays for
vials

Co-founded the Alliance to
Zero to pioneer supply
chain decarbonization
e.g. blister-free packaging concept
for prefillable syringe delivery

👤

~4.800
employees


>65
nationalities

>40%
female employees

~23 %
of leadership positions
held by women



Ownership



Executive Board

Dr. Christian Mias
CEO

Over 20 years leadership experience

CEO of SCHOTT Pharma since 2026

Previously Head of SCHOTT AG's
Electronic Packaging and Lighting &
Imaging business units

Ph.D. in Industrial Engineering

Reinhard Mayer
CFO

Over 30 years leadership experience

CFO of SCHOTT Pharma since 2025

Previous CFO roles with Nilfisk
Holding, Hansgrohe, and Getinge
Group

Master's Degree in Industrial
Engineering

¹ Absolute Scope 1 & 2 corporate carbon footprint reduction of SCHOTT Pharma vs. 2019 baseline (as of FY 2025)



SCHOTT Pharma's Governance

KGaA (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three corporate bodies:



General partner
(Komplementär)



Supervisory board
(Aufsichtsrat)



General shareholders' meeting
(Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

Supervisory Board

Shareholder representatives



Chairman

Peter Goldschmidt
CEO
Stada AG



Deputy Chairman

Dr. Wolfram Carius
Co-founder & advisor
Artistratis GmbH



Eva Kienle
Group CFO
Ramboll Group A/S



Ann-Kristin Erkens
CFO
SIG Group AG

Employee representatives



Mario Just
SCHOTT Pharma



Isabel Deister
SCHOTT Pharma

Press contact



Lea Kaiser



lea.kaiser@schott.com



+49 (0) 151/68 91 71 95



Katrin Schreyer



katrin.schreyer@schott.com



+49 (0) 171/11 67 54 4

